NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
about
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlVascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartmentsA tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functionsMerlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleusA Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue SarcomasThe role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implicationsNeurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.NF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin.Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasionUnfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressorStructural basis of DDB1-and-Cullin 4-associated Factor 1 (DCAF1) recognition by merlin/NF2 and its implication in tumorigenesis by CD44-mediated inhibition of merlin suppression of DCAF1 functionMerlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activityMerlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survivalTumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivatorsA crucial role of WW45 in developing epithelial tissues in the mouseThe tumor suppressor merlin is required for cell cycle exit, terminal differentiation, and cell polarity in the developing murine lensE-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components.Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.Salvador-Warts-Hippo pathway in a developmental checkpoint monitoring helix-loop-helix proteins.A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.Merlin/ERM proteins establish cortical asymmetry and centrosome position.The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex.E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactionsMerlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane.Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromesMolecular mechanisms promoting the pathogenesis of Schwann cell neoplasmsLoss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.Update on meningiomas.Frequency of loss of heterozygosity of the NF2 gene in schwannomas from Croatian patients.Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.PAK kinase regulates Rac GTPase and is a potential target in human schwannomasA cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesisThe role of Drosophila Merlin in spermatogenesisSignaling from the adherens junction.Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expressionMerlin is required for coordinating proliferation of two stem cell lineages in the Drosophila testis.A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formationGlobal Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation.
P2860
1f7a9270fc8d793bbd39ed1fb4c4a5beb6c481df20fc0c490e3c1ac0d9e319258fb0ab88ff4c412e30c44dc35682eb2281300ff91343d417e70c508a4e40e01c18024f3f0d53216fc07419c91d82f9008de04a0c9b446ebd57fa1bac892fdccb708d73e09912dcb7f49a4c89334024d7d86d75a5f9074926b5ba572d1176af77830fc60d514f50abf0ef645dc9a9e48ef7917bc4842f089eee40b3c6f61ed2ac
P248
Q24299106-77002BDD-EC23-4953-AD59-81905E9A7291Q24299236-5DAA81EF-B7C9-4BCE-8561-6918BC87E337Q24299493-B710C092-C62F-4054-9E37-F6010883980CQ24300692-51AFAEEE-733F-46B7-ACD3-2299B259F20EQ26782842-5147CA69-9F1C-41FA-AF13-7A60AB03DF77Q26783814-7C0EB20A-E0F3-4D04-87D2-EF6FB3EBA820Q26825296-C4B469DF-DB45-43DA-B24F-70FB583B8E2AQ27309867-34C43D1D-CD48-4AE9-ACAC-3EDE66392599Q27315878-871F77DF-D123-4D1D-94DD-77CD9EFF4988Q27675130-1C4CAC09-DBCD-4708-B7DE-224CFF86AD52Q27690668-C8CECA88-23E9-42F8-90AC-124DCA54D408Q28259936-F0BE820B-89FC-457F-A85E-3A9579E1BF4EQ28283076-85814ACD-4E9E-425A-84DD-20713A919332Q28504464-92D320EC-40BA-4FDD-9D2F-9945FCD77EB6Q28508988-0CF898B3-5E3A-4E4D-8034-13185976F5DEQ28590774-25D941A2-CD34-45BA-831C-323357BC390EQ28972461-6E41D65D-ED63-4086-ABE4-BE68FED93E99Q30364937-DD8CA0CA-7A03-4D20-8AAC-5C13D7FB54EBQ30392982-AFE4ABD4-0363-46D4-BCDF-A227968E341FQ30396975-9FFF0E8A-CFB6-499B-B9A7-D21DAA7898B1Q30418770-36B458B6-8E79-4C35-9DE4-52B3B9801E8FQ30429717-B3908FCC-81BC-493A-B2D3-4D5C33A3553BQ30443293-35E6D634-880D-4FB2-BA9C-CED2B31C0CE8Q30443407-4041317B-67E1-489D-8B88-1F978E9225C9Q30454537-857653AB-CEFB-4C96-8179-CAD07780C32CQ30457681-85F8B260-C65F-42AC-AAC6-37EF8C16FD9DQ30458195-C1E2F28A-BE5A-4C40-B587-145E1DDC3299Q30461960-130B5D98-5D84-4138-BFF8-50E8230DE48CQ30464398-888A5A50-0722-4BD1-8E48-023C2573A64BQ30474083-5241F0C8-BB9E-4CE7-AAAD-353B6291EE0DQ30490902-41B2EF50-6667-435C-9107-EA28FA539062Q30896529-CF28AF33-49D6-4BB6-8545-FBD863473090Q33314158-3E6FDCD2-9EDB-4509-8B3C-1853980253F6Q33652999-FD696500-642C-4139-BB2F-E95BA19A3E40Q33689582-4E435315-84A0-44A7-9387-63EFD1276E7AQ33707642-2437C869-0662-4BB6-AE69-BE32E117BDC1Q33747272-C081D798-ABBA-4532-83ED-D1769803FDDEQ33750138-ADF0AA61-0553-49CE-87C4-CF0AB6367472Q33809716-05678DCB-302D-4751-8CDE-554835EB0826Q33818953-A04D057A-DC28-46A3-BE14-B26F8018F5EE
P2860
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
description
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2003
@ast
im Mai 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2003/05/01)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/05/01)
@nl
наукова стаття, опублікована в травні 2003
@uk
مقالة علمية (نشرت في مايو 2003)
@ar
name
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@ast
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@en
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@nl
type
label
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@ast
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@en
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@nl
prefLabel
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@ast
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@en
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@nl
P2093
P2860
P921
P356
P1433
P1476
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
@en
P2093
Andrea I. McClatchey
Dominique Lallemand
Ichiko Saotome
Marcello Curto
Marco Giovannini
P2860
P304
P356
10.1101/GAD.1054603
P577
2003-05-01T00:00:00Z